Download PDF
Semin Liver Dis 2022; 42(02): 151-158
DOI: 10.1055/s-0042-1745871
Review Article

Liver Dysfunction in COVID-19: From Onset to Recovery

Wen-Zheng Yuan
1   Department of Gastrointestinal Surgery II, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China
,
Tao Fu
1   Department of Gastrointestinal Surgery II, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints


Abstract

With the spread of coronavirus disease 2019 (COVID-19) worldwide, extrapulmonary lesions, including liver dysfunction, have attracted growing attention. The mechanisms underlying liver dysfunction in COVID-19 remain unclear. The reported prevalence of liver dysfunction varies widely across studies. In addition, its impact on clinical outcomes and its recovery after discharge are still controversial. In this review, pathological and laboratory findings were analyzed to reveal the potential mechanisms of COVID-19-induced liver injury from onset to recovery. Four patterns of liver damage were summarized according to the pathological findings, including hypoxemia and shock changes, vascular thrombosis and vascular damage, bile duct damage, and other histological changes. With a strict definition, the prevalence of liver dysfunction was not as high as reported. Meanwhile, liver dysfunction improved during the process of recovery. Nevertheless, the definite liver dysfunction was significantly associated with severe clinical course, which should not be ignored.

Keywords

COVID-19 - hepatic insufficiency - pathology - prevalence - convalescence

Authors' Contributions

T.F. designed the review; W.Z.Y. drafted the manuscript; T.F. critically revised the paper.


Supplementary Material



Publication History

Article published online:
23 June 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Organization WH. WHO Coronavirus Disease (COVID-19) Dashboard [February 3, 2022] 2022. Accessed February 3, 2022 at: https://covid19.who.int/
    PubMedGoogle Scholar
  • 2 Papadopoulos N, Vasileiadi S, Deutsch M. COVID-19 and liver injury: where do we stand?. Ann Gastroenterol 2020; 33 (05) 459-464
    PubMedGoogle Scholar
  • 3 Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol 2021; 33 (03) 309-311
    CrossrefPubMedGoogle Scholar
  • 4 Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United Eur Gastroenterol J 2020; 8 (05) 509-519
    CrossrefPubMedGoogle Scholar
  • 5 Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: a comprehensive review. World J Gastroenterol 2020; 26 (19) 2323-2332
    CrossrefPubMedGoogle Scholar
  • 6 Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: etiology, treatment and prognosis. World J Gastroenterol 2020; 26 (19) 2286-2293
    CrossrefPubMedGoogle Scholar
  • 7 Abenavoli L, Gentile I, Maraolo AE, Negro F. SARS-CoV-2 and liver damage: a possible pathogenetic link. Hepatobiliary Surg Nutr 2020; 9 (03) 322-324
    CrossrefPubMedGoogle Scholar
  • 8 Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020; 5 (06) 529-530
    CrossrefPubMedGoogle Scholar
  • 9 Kullar R, Patel AP, Saab S. Hepatic injury in patients with COVID-19. J Clin Gastroenterol 2020; 54 (10) 841-849
    CrossrefPubMedGoogle Scholar
  • 10 Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol 2021; 56 (03) 218-230
    CrossrefPubMedGoogle Scholar
  • 11 Sikkema BJB, Sint Nicolaas JJ, van Wijngaarden PP. No association between COVID-19 related liver injury and the course of disease: a retrospective study. Scand J Gastroenterol 2021; 56 (01) 68-71
    CrossrefPubMedGoogle Scholar
  • 12 Zhan K, Liao S, Li J. et al. Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation. Gut 2021; 70 (03) 628-629
    CrossrefPubMedGoogle Scholar
  • 13 Wang Y, Lu F, Zhao J. Reply to: Correspondence relating to “SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19”. J Hepatol 2020; 73 (04) 996-998
    CrossrefPubMedGoogle Scholar
  • 14 Roedl K, Jarczak D, Drolz A. et al. Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?. Ann Intensive Care 2021; 11 (01) 44
    CrossrefPubMedGoogle Scholar
  • 15 Marjot T, Webb GJ, Barritt IV AS. et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021; 18 (05) 348-364
    CrossrefPubMedGoogle Scholar
  • 16 Fu T, Deng M, Wang X, Yang F. Predictor of poor prognosis of COVID-19 patients - liver injury. Expert Rev Gastroenterol Hepatol 2020; 14 (10) 873-876
    CrossrefPubMedGoogle Scholar
  • 17 Koskinas J, Gomatos IP, Tiniakos DG. et al. Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 2008; 14 (09) 1389-1393
    CrossrefPubMedGoogle Scholar
  • 18 Torgersen C, Moser P, Luckner G. et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg 2009; 108 (06) 1841-1847
    CrossrefPubMedGoogle Scholar
  • 19 Lagana SM, Kudose S, Iuga AC. et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 2020; 33 (11) 2147-2155
    CrossrefPubMedGoogle Scholar
  • 20 Díaz LA, Idalsoaga F, Cannistra M. et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data. World J Gastroenterol 2020; 26 (48) 7693-7706
    CrossrefPubMedGoogle Scholar
  • 21 Lax SF, Skok K, Zechner P. et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome : results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 2020; 173 (05) 350-361
    CrossrefPubMedGoogle Scholar
  • 22 Duarte-Neto AN, Monteiro RAA, da Silva LFF. et al. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. Histopathology 2020; 77 (02) 186-197
    CrossrefPubMedGoogle Scholar
  • 23 Yan J, Li S, Li S. The role of the liver in sepsis. Int Rev Immunol 2014; 33 (06) 498-510
    CrossrefPubMedGoogle Scholar
  • 24 Sonzogni A, Previtali G, Seghezzi M. et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int 2020; 40 (09) 2110-2116
    CrossrefPubMedGoogle Scholar
  • 25 Rapkiewicz AV, Mai X, Carsons SE. et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine 2020; 24: 100434
    CrossrefPubMedGoogle Scholar
  • 26 Zhao CL, Rapkiewicz A, Maghsoodi-Deerwester M. et al. Pathological findings in the postmortem liver of patients with coronavirus disease 2019 (COVID-19). Hum Pathol 2021; 109: 59-68
    CrossrefPubMedGoogle Scholar
  • 27 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
    CrossrefPubMedGoogle Scholar
  • 28 Fiel MI, El Jamal SM, Paniz-Mondolfi A. et al. Findings of hepatic severe acute respiratory syndrome coronavirus-2 infection. Cell Mol Gastroenterol Hepatol 2021; 11 (03) 763-770
    CrossrefPubMedGoogle Scholar
  • 29 Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020; 18 (09) 2128-2130 .e2
    CrossrefPubMedGoogle Scholar
  • 30 Loganathan S, Kuppusamy M, Wankhar W. et al. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes. Respir Physiol Neurobiol 2021; 283: 103548
    CrossrefPubMedGoogle Scholar
  • 31 Yang L, Han Y, Nilsson-Payant BE. et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 2020; 27 (01) 125-136 .e7
    CrossrefPubMedGoogle Scholar
  • 32 Zhao B, Ni C, Gao R. et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell 2020; 11 (10) 771-775
    CrossrefPubMedGoogle Scholar
  • 33 Liu YL, Ren J, Yuan JP. et al. Postoperative onset and detection of SARS-CoV-2 in surgically resected specimens from gastrointestinal cancer patients with pre/asymptomatic COVID-19. Ann Surg 2020; 272 (06) e321-e328
    CrossrefPubMedGoogle Scholar
  • 34 Wang Y, Liu S, Liu H. et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020; 73 (04) 807-816
    CrossrefPubMedGoogle Scholar
  • 35 Bangash MN, Patel JM, Parekh D. et al. SARS-CoV-2: is the liver merely a bystander to severe disease?. J Hepatol 2020; 73 (04) 995-996
    CrossrefPubMedGoogle Scholar
  • 36 Chornenkyy Y, Mejia-Bautista M, Brucal M. et al. Liver pathology and SARS-CoV-2 detection in formalin-fixed tissue of patients with COVID-19. Am J Clin Pathol 2021; 155 (06) 802-814
    CrossrefPubMedGoogle Scholar
  • 37 Roth NC, Kim A, Vitkovski T. et al. Post-COVID-19 cholangiopathy: a novel entity. Am J Gastroenterol 2021; 116 (05) 1077-1082
    CrossrefPubMedGoogle Scholar
  • 38 Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep 2020; 13 (11) e237984
    CrossrefPubMedGoogle Scholar
  • 39 Durazo FA, Nicholas AA, Mahaffey JJ. et al. Post-Covid-19 cholangiopathy-a new indication for liver transplantation: a case report. Transplant Proc 2021; 53 (04) 1132-1137
    CrossrefPubMedGoogle Scholar
  • 40 Galiero R, Pafundi PC, Simeon V. et al; COVOCA Study Group. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: findings from COVOCA study. PLoS One 2020; 15 (12) e0243700
    CrossrefPubMedGoogle Scholar
  • 41 Tian S, Xiong Y, Liu H. et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020; 33 (06) 1007-1014
    CrossrefPubMedGoogle Scholar
  • 42 Schaller T, Hirschbühl K, Burkhardt K. et al. Postmortem examination of patients with COVID-19. JAMA 2020; 323 (24) 2518-2520
    CrossrefPubMedGoogle Scholar
  • 43 Remmelink M, De Mendonça R, D'Haene N. et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care 2020; 24 (01) 495
    CrossrefPubMedGoogle Scholar
  • 44 Kleiner DE, Chalasani NP, Lee WM. et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59 (02) 661-670
    CrossrefPubMedGoogle Scholar
  • 45 Kullak-Ublick GA, Andrade RJ, Merz M. et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66 (06) 1154-1164
    CrossrefPubMedGoogle Scholar
  • 46 Kleiner DE. Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clin Liver Dis (Hoboken) 2014; 4 (01) 12-16
    CrossrefPubMedGoogle Scholar
  • 47 Cai Q, Huang D, Yu H. et al. COVID-19: abnormal liver function tests. J Hepatol 2020; 73 (03) 566-574
    CrossrefPubMedGoogle Scholar
  • 48 Fan Z, Chen L, Li J. et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 2020; 18 (07) 1561-1566
    CrossrefPubMedGoogle Scholar
  • 49 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8 (04) 420-422
    CrossrefPubMedGoogle Scholar
  • 50 Kleiner DE. Liver biopsy shines a light on COVID-19-related liver injury. Cell Mol Gastroenterol Hepatol 2021; 11 (03) 881-882
    CrossrefPubMedGoogle Scholar
  • 51 Ye Z, Song B. COVID-19 related liver injury: call for international consensus. Clin Gastroenterol Hepatol 2020; 18 (12) 2848-2851
    CrossrefPubMedGoogle Scholar
  • 52 Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int 2021; 41 (01) 20-32
    CrossrefPubMedGoogle Scholar
  • 53 Seow JJW, Pai R, Mishra A. et al. Single-Cell RNA-seq reveals angiotensin-converting enzyme 2 and transmembrane serine protease 2 expression in TROP2+ liver progenitor cells: implications in coronavirus disease 2019-associated liver dysfunction. Front Med (Lausanne) 2021; 8: 603374
    CrossrefPubMedGoogle Scholar
  • 54 Shao J, Liang Y, Li Y. et al. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hepatol Int 2021; 15 (01) 202-212
    CrossrefPubMedGoogle Scholar
  • 55 Nakanishi T, Pigazzini S, Degenhardt F. et al; FinnGen; COVID-19 Host Genetics Initiative (HGI). Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest 2021; 131 (23) e152386
    CrossrefPubMedGoogle Scholar
  • 56 Bianco C, Baselli G, Malvestiti F. et al. Genetic insight into COVID-19-related liver injury. Liver Int 2021; 41 (01) 227-229
    CrossrefPubMedGoogle Scholar
  • 57 Machill A, Bals R, Lammert F, Krawczyk M. Genetic insight into COVID-19 related liver injury: a note on MBOAT7. Liver Int 2021; 41 (05) 1157-1159
    CrossrefPubMedGoogle Scholar
  • 58 Valenti L, Griffini S, Lamorte G. et al. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun 2021; 117: 102595
    CrossrefPubMedGoogle Scholar
  • 59 Liu J, Wang T, Cai Q. et al. Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res 2020; 50 (11) 1211-1221
    CrossrefPubMedGoogle Scholar
  • 60 Alqahtani SA, Buti M. COVID-19 and hepatitis B infection. Antivir Ther 2020; 25 (08) 389-397
    CrossrefPubMedGoogle Scholar
  • 61 Onorato L, Pisaturo M, Camaioni C. et al. Risk and prevention of hepatitis B virus reactivation during immunosuppression for non-oncological diseases. J Clin Med 2021; 10 (21) 5201
    CrossrefPubMedGoogle Scholar
  • 62 Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148 (01) 215-219 , quiz e16–e17
    CrossrefPubMedGoogle Scholar
  • 63 Wong GL, Yuen BW, Chan HL. et al. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int 2019; 39 (02) 271-279
    CrossrefPubMedGoogle Scholar
  • 64 Campbell C, Andersson MI, Ansari MA. et al. Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era. Front Med (Lausanne) 2021; 8: 706482
    CrossrefPubMedGoogle Scholar
  • 65 Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: a hepatology perspective. World J Gastroenterol 2020; 26 (46) 7272-7286
    CrossrefPubMedGoogle Scholar
  • 66 Anastasiou OE, Korth J, Herbstreit F, Witzke O, Lange CM. Mild versus severe liver injury in SARS-CoV-2 infection. Dig Dis 2021; 39 (01) 52-57
    CrossrefPubMedGoogle Scholar
  • 67 Philips CA, Mohan N, Ahamed R. et al. One disease, many faces-typical and atypical presentations of SARS-CoV-2 infection-related COVID-19 disease. World J Clin Cases 2020; 8 (18) 3956-3970
    CrossrefPubMedGoogle Scholar
  • 68 Bloom PP, Meyerowitz EA, Reinus Z. et al. Liver biochemistries in hospitalized patients with COVID-19. Hepatology 2021; 73 (03) 890-900
    CrossrefPubMedGoogle Scholar
  • 69 Lei F, Liu YM, Zhou F. et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020; 72 (02) 389-398
    CrossrefPubMedGoogle Scholar
  • 70 Li G, Xu Y, Yang YT, Liu PF. Prevalence of acute liver injury and hypertransaminemia in patients with COVID-19: a protocol for a systematic review. BMJ Open 2020; 10 (07) e040517
    CrossrefPubMedGoogle Scholar
  • 71 Li G, Yang Y, Gao D, Xu Y, Gu J, Liu P. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci 2021; 18 (05) 1285-1296
    CrossrefPubMedGoogle Scholar
  • 72 Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (05) 2620-2629
    CrossrefPubMedGoogle Scholar
  • 73 Suresh Kumar VC, Harne PS, Mukherjee S. et al. Transaminitis is an indicator of mortality in patients with COVID-19: a retrospective cohort study. World J Hepatol 2020; 12 (09) 619-627
    CrossrefPubMedGoogle Scholar
  • 74 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46 (12) 2050-2068
    CrossrefPubMedGoogle Scholar
  • 75 Kaneko S, Kurosaki M, Nagata K. et al. Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity. PLoS One 2020; 15 (11) e0241663
    CrossrefPubMedGoogle Scholar
  • 76 Medetalibeyoglu A, Catma Y, Senkal N. et al. The effect of liver test abnormalities on the prognosis of COVID-19. Ann Hepatol 2020; 19 (06) 614-621
    CrossrefPubMedGoogle Scholar
  • 77 Liu C, He Y, Liu L, Li F, Shi Y. Children with COVID-19 behaving milder may challenge the public policies: a systematic review and meta-analysis. BMC Pediatr 2020; 20 (01) 410
    CrossrefPubMedGoogle Scholar
  • 78 Meena J, Yadav J, Saini L, Yadav A, Kumar J. Clinical features and outcome of SARS-CoV-2 infection in children: a systematic review and meta-analysis. Indian Pediatr 2020; 57 (09) 820-826
    CrossrefPubMedGoogle Scholar
  • 79 Kulkarni AV, Kumar P, Tevethia HV. et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther 2020; 52 (04) 584-599
    CrossrefPubMedGoogle Scholar
  • 80 Zarifian A, Zamiri Bidary M, Arekhi S. et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis. J Med Virol 2021; 93 (01) 336-350
    CrossrefPubMedGoogle Scholar
  • 81 Ye L, Chen B, Wang Y. et al. Prognostic value of liver biochemical parameters for COVID-19 mortality. Ann Hepatol 2021; 21: 100279
    CrossrefPubMedGoogle Scholar
  • 82 Kumar A, Arora A, Sharma P. et al. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: a systematic review and meta-analysis. Indian J Gastroenterol 2020; 39 (03) 268-284
    CrossrefPubMedGoogle Scholar
  • 83 Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: a systematic review and meta-analysis. J Clin Gastroenterol 2021; 55 (01) 67-76
    CrossrefPubMedGoogle Scholar
  • 84 Phipps MM, Barraza LH, LaSota ED. et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology 2020; 72 (03) 807-817
    CrossrefPubMedGoogle Scholar
  • 85 Ding ZY, Li GX, Chen L. et al; Tongji Multidisciplinary Team for Treating COVID-19 (TTTC). Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol 2021; 74 (06) 1295-1302
    CrossrefPubMedGoogle Scholar
  • 86 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397 (10270): 220-232
    CrossrefPubMedGoogle Scholar
  • 87 Weng J, Li Y, Li J. et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol 2021; 6 (05) 344-346
    CrossrefPubMedGoogle Scholar
  • 88 Daugherty SE, Guo Y, Heath K. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2021; 373 (1098): n1098
    CrossrefPubMedGoogle Scholar
  • 89 Mao K, Tan Q, Ma Y. et al. Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 months of recovery. Cell Death Dis 2021; 12 (06) 541
    CrossrefPubMedGoogle Scholar
  • 90 Arnold DT, Hamilton FW, Milne A. et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021; 76 (04) 399-401
    CrossrefPubMedGoogle Scholar
  • 91 Dennis A, Wamil M, Alberts J. et al; COVERSCAN study investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open 2021; 11 (03) e048391
    CrossrefPubMedGoogle Scholar
  • 92 Falasca L, Nardacci R, Colombo D. et al. Postmortem findings in Italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities. J Infect Dis 2020; 222 (11) 1807-1815
    CrossrefPubMedGoogle Scholar
  • 93 Bradley BT, Maioli H, Johnston R. et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet 2020; 396 (10247): 320-332
    CrossrefPubMedGoogle Scholar
  • 94 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 173 (04) 268-277
    CrossrefPubMedGoogle Scholar
  • 95 Martines RB, Ritter JM, Matkovic E. et al; COVID-19 Pathology Working Group. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis 2020; 26 (09) 2005-2015
    CrossrefPubMedGoogle Scholar
  • 96 Beigmohammadi MT, Jahanbin B, Safaei M. et al. Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients. Int J Surg Pathol 2021; 29 (02) 135-145
    CrossrefPubMedGoogle Scholar
  • 97 Buja LM, Wolf DA, Zhao B. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol 2020; 48: 107233
    CrossrefPubMedGoogle Scholar